Image of Carole Mitnick

Carole Diane Mitnick, Sc.D.

Dr. Mitnick graduated cum laude from the University of Rochester in 1988 with a B.A. in political science and French. She spent 1986-1987 in Paris, France, studying at L’Institut d’Etudes Politiques and L’Université de Paris IV. In 1996, she received a masters in international health epidemiology and ecology from the Harvard School of Public Health, and in 2001 she completed a doctor of science degree in international health epidemiology and ecology, also at the Harvard School of Public Health.

Dr. Mitnick’s research centers on the improvement of clinical management and programmatic policy for tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. Dr. Mitnick is a founding investigator of a movement to conduct randomized controlled clinical trials to improve treatment of drug-resistant TB (RESIST-TB). Dr. Mitnick’s work also includes applying marginal structural modeling to MDR-TB treatment data to assess the effect on outcomes of different types of therapy in observational studies. Dr. Mitnick is the principal investigator of an NIAID grant to plan a Phase II clinical trial examining the potential of high-dose rifampin to shorten standard TB therapy. Her research questions are strongly influenced by the mission of Partners In Health, with which Dr. Mitnick has worked since 1996: she strives to conduct research that will effect changes in global policy to ensure the highest standard of care and best treatment outcomes for patients suffering from all forms of tuberculosis, regardless of where they live.

This influence has also driven Dr. Mitnick’s involvement in global policy efforts. She contributed to the original and revised Guidelines for the Programmatic Management of MDR-TB. She sought, through the publication, Randomized trials to optimize treatment of MDR-TB: the time for action is now (PLoS Medicine, 2007), to generate increased support for controlled examination of anti-mycobacterial agents for the treatment of MDR-TB. Through participation in working groups, sub-groups, and task forces of the STOP-TB Partnership, she has co-authored two articles which define research agendas for MDR-TB (Gupta et al., IJTLD, 2003; Cobelens et al., PLoS Medicine 2008) and one that proposed standardized definitions for analysis of MDR-TB treatment outcomes (Laserson et al., IJTLD, 2005). She consults for the Green Light Committee of the World Health Organization for francophone countries implementing programmatic management of MDR-TB. Her efforts extend to capacity building for recording and reporting on the management of drug-resistant TB, as well as to clinical and operational research in Latin America and beyond. She develops and participates in post-graduate trainings, network-building activities, and trial protocols to be implemented within settings of national TB programs around the world.

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.
Authors: Authors: Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A.
Lancet Child Adolesc Health
View full abstract on Pubmed
Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho.
Authors: Authors: Oyewusi L, Zeng C, Seung KJ, Mpinda S, Kunda M, Mitnick CD, Kanu M, Tamirat M, Makaka J, Mofolo M, Maime R, Maama L, Senyo N, Oguntoyinbo B, Mayombo L, Franke MF.
Glob Health Action
View full abstract on Pubmed
The Frequency and Incidence of QT Prolongation with Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort.
Authors: Authors: Khan U, Rich M, Franke M, Lachenal N, Ahmed S, Bekele A, Isani AK, Hewison C, Sari CYI, Tan CL, Varaine F, Flores EH, Putri FA, Faqirzai J, Beauchamp J, Vo LNQ, Siddiqui MR, Seung K, Bastard M, Nkunkanyirazo P, Kiria N, Khan M, Algozhin Y, Melikyan N, Saki NA, Vilbrun SC, Fatima R, Naing YY, Islam S, Mamsa S, Mitnick C, Huerga H, Khan PY.
Clin Infect Dis
View full abstract on Pubmed
Revealing disparities in representation in knowledge generation and guideline development.
Authors: Authors: Almeida CPB, Andom AT, Casseus A, Do JM, Gelin A, Lecca L, Luma M, Mazzi M, Mitnick CD, Mugunga JC, Ndayizigiye M, Nguyen N, Tamirat M, Tefera G, Toussaint S, Tovar M, Tzelios C.
BMC Health Serv Res
View full abstract on Pubmed
Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.
Authors: Authors: Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, Bektasov S, LaHood A, Arlyapova N, Osso E, Yedilbayev A, Korotych O, Ciobanu A, Skrahina A, Mitnick CD, Seung KJ, Algozhin Y, Rich ML.
Clin Infect Dis
View full abstract on Pubmed
Target regimen profiles for tuberculosis treatment.
Authors: Authors: Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG.
Bull World Health Organ
View full abstract on Pubmed
A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB.
Authors: Authors: Vasquez A, Mitnick C, Nyaruhirira AU, Chiang CY, Horsburgh CR.
IJTLD Open
View full abstract on Pubmed
Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
Authors: Authors: Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, Mitnick CD, Rich ML, Islam S, Zhizhilashvili D, Yeghiazaryan L, Nikolenko EN, Zarli K, Adnan S, Salahuddin N, Ahmed S, Vargas ZHR, Bekele A, Shaimerdenova A, Tamirat M, Gelin A, Vilbrun SC, Hewison C, Khan U, Franke M.
Nat Commun
View full abstract on Pubmed
Reduced critical concentration might not have improved MGIT-based DST's sensitivity to rifampicin.
Authors: Authors: Rupasinghe P, Ashraf A, Barreda N, Parveen S, Zubair M, Calderon R, Asif S, Hirani N, Chingisova L, Bulane A, Hang PT, Ha DT, Ardizzoni E, Kursheed N, De Rijk WB, Rigouts L, Guglielmetti L, Mitnick C, de Jong BC.
Antimicrob Agents Chemother
View full abstract on Pubmed
Beyond goodwill and promises-urgent needs and opportunities to accelerate the fight against tuberculosis in Brazil.
Authors: Authors: Almeida CPB, Trajman A, Mitnick CD, Kritski AL, Santos-Filho ETD.
Lancet Reg Health Am
View full abstract on Pubmed